Position in GSK
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$948,802
+$504,470 QoQ
Shares Held
18,100
+75.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.63%
of 13F equity value
Holder Rank
#358
of 1,033 holders
Holding Since
Mar 2021
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GSK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bayesian Capital Management, LP holds $5,153,335 across 7 Drug Manufacturers - General names. GSK ranks #3 (18.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
9,100 | $1,149,694 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
19,200 | $1,106,304 | |
| 3 | GSK |
GSK plc
This page
|
18,100 | $948,802 | |
| 4 | AMGN |
Amgen Inc
|
2,384 | $863,294 | |
| 5 | NVO |
Novo Nordisk A S
|
8,500 | $407,490 | |
| 6 | NVS |
Novartis AG
|
2,365 | $370,642 | |
| 7 | SNY |
Sanofi
|
7,199 | $307,109 |
All Filings in GSK
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $948,802 | 18,100 | Shares | Sole | 2026-08-14 | |
| 2025-09-30 | $444,332 | 10,295 | Shares | Sole | 2025-11-14 | |
| 2025-03-31 | $613,525 | 15,837 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $474,731 | 14,037 | Shares | Sole | 2025-02-14 | |
| 2023-06-30 | $374,220 | 10,500 | Shares | Sole | 2023-08-14 | |
| 2022-12-31 | $854,604 | 24,320 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $1,510,347 | 51,320 | Shares | Sole | 2022-11-14 | |
| 2021-03-31 | $1,219,040 | 34,825 | Shares | Sole | 2021-05-14 | |
| No filing history on record for this holder in this stock. | ||||||